Erratum: Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies

Nature Clinical Practice Gastroenterology & Hepatology (2008) 5: 250–267 [doi:10.1038/ncpgasthep1097]

Corrigendum

In the May 2008 issue, in the Review by Reinacher-Schick et al., there was an error in the response rate figures reported for the study by Saltz et al.⁹⁵ in Table 2 on page 257. The correct response rates should be 38% versus 38% instead of 46.5% versus 37.5% as shown in the corrected Table 2 below. The Saltz et al. paper was available in abstract form only at the time of publication, but has now been published in full; the updated reference details are included below.⁹⁵

Table 2 Examples of recent trials with the VEGF-specific antibody bevacizumab.